Ph.D., CEO, COMBiNATi
Biography
Dr. Hung is an entrepreneur specializing in microfluidic platform technology development. He has 14 years of life science leadership experience in product development, R&D management, and bringing innovation from lab to marketplace. He was the co-founder and CTO of CellASIC, which was acquired by Merck KGaA, and served as the Head of Microfluidics in the Life Science Workflow division. He received his PhD in Electrical Engineering and Computer Science from UC Berkeley, and B.S. degree in Electrical Engineering from National Taiwan University.
Clinical & Research Tools Showcase:
COMBiNATi
The COMBiNATi |Q|&A platform is the only digital PCR platform with an identical workflow to traditional qPCR. Enhance your nucleic acid quantification without sacrificing precious sample, time, or reagents.
Introducing The |Q|&A Platform. Digital PCR Re-Imagined
COMBiNATi has developed the only dPCR system with a qPCR-equivalent workflow: one-step post-sample prep, no additional hands-on time, <90 minutes time-to-answer. With improved multiplexing and near-zero sample waste, COMBiNATi’s |Q|&A platform will change how you think about digital PCR.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 23 4.30 P.M.-4.45 P.M.,Track 7 - January 24 9.00 A.M.-10.45 A.M.
The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
